Journal article

The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications

William Vainchenker, Isabelle Plo, Caroline Marty, Leila N Varghese, Stefan N Constantinescu

EXPERT REVIEW OF HEMATOLOGY | TAYLOR & FRANCIS LTD | Published : 2019

Abstract

Introduction: Classical Myeloproliferative Neoplasms (MPNs) include three disorders: Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). MPNs are associated with constitutive activation of JAK2 leading to persistent cell signaling downstream of the dimeric myeloid cytokine receptors due to mutations in three genes encoding JAK2, calreticulin (CALR) and the thrombopoietin (TPO) receptor (MPL or TPOR). CALR and MPL mutants induce JAK2 activation that depends on MPL expression, thus explaining why they induce megakaryocyte pathologies including ET and PMF, but not PV. In contrast, JAK2 V617F drives all three diseases as it induces persistent signaling via EPO..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Fondation les avions de Sebastien


Funding Acknowledgements

This paper was funded by Fondation les avions de Sebastien [ARC 16/21-073], Institut National de la Sante et de la Recherche Medicale, Institut National Du Cancer (PLBIO 2017), Ligue Nationale contre le Cancer (Equipe labellisee) the GR-Ex which is funded by the program "Investissement d'Avenir" and Walloon Excellence in Life Sciences and Biotechnology.